Corrigendum to "Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature" [Leuk. Res. 33 (2009) 1627-1635] (DOI:10.1016/j.leukres.2009.02.015);Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1627-1635

  Paydas, Semra ^a   Ergin, Melek ^a   Seydaoglu, Gulsah ^a   Erdogan, Seyda ^a   Yavuz, Sinan ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Angiogenesis; Cox 2; EBV; Lymphangiogenesis; Lymphoma; Prognosis; Survivin; TSP 1; VEGF A; VEGF C

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOOXYGENASE 2; LACTATE DEHYDROGENASE; SURVIVIN; THROMBOSPONDIN 1; VASCULOTROPIN A; VASCULOTROPIN C; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ADULT; AGE; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL RATE; APOPTOSIS; LYMPH NODE METASTASIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; SURVIVAL; VIROLOGY;

APOPTOSIS; CYCLOOXYGENASE 2; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70249113006     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.014     Document Type: Erratum

References (93)

1. Paepe P.D., and Wolf-Peeters C.D. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin's lymphomas comprising several distinct clinicopathological entities. Leukemia 21 (2007) 37-43
2. Paydas S., Ergin M., Erdogan S., Seydaoglu G., Yavuz S., and Disel U. Trombospondin-1 (TSP-1) and survivin (S) expression in non-Hodgkin's lymphomas. Leuk Res 32 (2008) 243-250
3. Paydas S., Ergin M., Erdogan S., and Seydaoglu G. Prognostic significance of EBV-LMP-1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res 32 (2008) 1424-1430
4. Paydas S., Ergin M., Erdogan S., and Seydaoglu G. Cylooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma 48 (2007) 389-395
5. Paydas S, Seydaoglu G, Ergin M, Erdogan S. Prognostic significance of VEGF-A and VEGF-C in non-Hodgkin's lymphomaa and review of the literature. Leuk Lymphoma; in press.
6. Yamamoto H., Ngan C.Y., and Monden M. Cancer cells survive with surviving. Cancer Sci 99 (2008) 1709-1714
7. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
8. Xiang X.J., He Y.J., Li Y.H., Huang H., and Xu F. Clinical significance of survivin expression in peripheral T-cell lymphoma. Ai Zheng 25 (2006) 758-761
9. Xiang X.J., and He Y.J. Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi 28 (2006) 298-301
10. Li J.F., Li G.D., Liu W.P., Wang Y., Cheng J.R., Chen Y., et al. Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance. Zhonghua Bing Li Xue Za Zhi 35 (2006) 213-217
11. Schlette E.J., Mederios L.J., Goy A., Lai R., and Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol 22 (2004) 1682-1688
12. Zuo X.L., Zhou X., Meng J., Zhang K.J., Liu X.H., and Yang H.Q. A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma. Zhonghua Nei Ke Za Zhi 45 (2006) 133-135
13. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
14. Kuttler F., Valnet-Rabier M.B., Angonin R., Ferrand C., Deconinck E., Mougin C., et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16 4 (2002) 726-735
15. Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., et al. Survivin and its prognostic significance in pediatric acute lymphoblastic leukemia. Haematologica 92 (2007) 1043-1050
16. Romagnoli M., Trichet V., David C., Clement M., Moreau P., Batallie R., et al. Significant impact of survivin on myeloma cell growth. Leukemia 21 (2007) 1070-1078
17. Liu L., Zhang M., and Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 48 (2007) 2179-2183
18. Caldas H., Fangusaro J.R., Boue D.R., Holloway M.P., and Altura R.A. Dissecting the role of endothelial survivin Ex3 in angiogenesis. Blood 109 (2007) 1479-1489
19. Mita A.C., Mita M.M., Nawrocki S.T., and Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14 (2008) 5000-5005
20. Kuttler F., Valnet-Rabier M.B., Angonin R., Ferrand C., Deconinck E., Mougin C., et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16 (2002) 726-735
21. Watanuki-Miyauchi R., Kojima Y., Tsurumi H., Hara T., Goto N., Kasahara S., et al. Expression of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 55 (2005) 324-330
22. Mainou-Fowler T., Overman L.M., Dignum H., Wood K., Crosier S., Angus B., et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32 (2008) 59-68
23. Tracey L., Perez-Rosado A., Artiga M.J., Camacho F., Rodriguez A., Martinez N., et al. Expression of the NF-k B targets BCL2 and BIRC5/survivin characterizes small B cell and aggressive B-cell lymphomas, respectively. J Pathol 206 (2005) 123-134
24. Martinez A., Bellesillo B., Bosch F., Ferrer A., Marce S., Villamor N., et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164 (2004) 501-510
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and molecular regulation. Nat Med 1 (1995) 27-31
26. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh I., Cao Y., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16 (1997) 3898-3911
27. Ellis I., and Filde I. Angiogenesis and metastasis. Eur J Cancer 32A (1996) 2451-2460
28. Beck L.J., and D'Amore P. Vascular development: cellular and molecular regulation. FASEB J 11 (1997) 365-373
29. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
30. Zhang X.H., Huang D.P., Guo G.L., Chen G.R., Zhang H.X., Wan L., et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 8 (2008) 4
31. Mohammed R.A.A., Green A., El-Shikh S., Paish E.C., Ellis I.O., and Martin S.G. Prognostic significance of vascular endothelial cell growth factors-A, C, and-D in breast cancer and their relationship with angi- and lymphangiogenesis. Br J Cancer (2007) 1092-1100
32. Salven P., Teerenhovi L., and Joensun H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
33. Kini A.R., Day N.E., and Peterson L.C. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 14 (2000) 1414-1418
34. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 28 (2004) 595-604
35. Ho C.L., Sheu L.F., and Li C.Y. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 10 (2002) 316-321
36. Moehler T.M., Ho A.D., Goldschmidt H., and Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 45 (2003) 227-244
37. Jorgensen J.M., Sorensen F.B., Bendix K., Nielsen J.L., Olsen M.L., Funder A.M.D., et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48 (2007) 584-595
38. Korkolopoulou P., Thymara I., Kavantzas N., Vassilakopoulos T.P., Kokoris S.I., Dmitriadou E.M., et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 1 (2005) 894-900
39. Hazar B., Paydas S., Zorludemir S., Sahin B., and Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 44 (2003) 2089-2093
40. Gratzinger D., Zhao S., Marinelli R.J., Kapp A.V., Tibshirani R.J., Hammer A.S., et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B cell lymphoma subtypes. Am J Pathol 170 (2007) 1362-1369
41. Ganjoo K.N., Moore A.M., Orazi A., Sen J.A., Johnson C.S., and An C.S. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 134 (2008) 381-387
42. Jørgensen J.M., Sørensen F.B., Bendix K., Nielsen J.L., Olsen M.L., Funder A.M., et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48 (2007) 584-595
43. Gratzinger D., Zhao S., Marinelli R.J., Kapp A.V., Tibshirani R.J., Hammer A.S., et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 170 (2007) 1362-1369
44. Sundar S.S., and Ganesan T.S. Role of lymphangiogenesis in cancer. J Clin Oncol 25 (2007) 4299-4307
45. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196 (2002) 1497-1506
46. Jeltsch M., Kaipinen A., Joukov V., Meng X., Lakso M., Rauvala H., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 (1997) 1423-1425
47. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E., Weich H.A., Christ B., et al. VEGF- and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188 (1997) 96-109
48. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Brown L.F., and Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201 (2005) 1089-1099
49. Pazgal I., Boycov O., Shpilberg O., Okon E., and Bairey O. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 48 (2007) 2213-2220
50. Murono S., Inoue H., Tanabe T., Joab I., Yoshizaki T., Furukawa M., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved vascular endothelial growth factor production in nasopharyngeal carcinoma cells. PNAS 98 (2001) 6905-6910
51. Park S., Lee J., Ko Y.H., Han A., Jun H.J., Lee S.C., et al. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood 110 (2007) 972-978
52. Tzankov A., Heiss S., Ebner S., Sterlacci W., Schaefer G., Augustin F., et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol 60 (2007) 476-482
53. Kudowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 130 (2005) 86-877
54. Yamauchi M., Imajoh-Ohmi S., and Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci 98 (2007) 1491-1497
55. Merle B., Malaval L., Lawler J., Delmas P., and Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTRdependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Biochem 67 (1997) 75-83
56. Clezardin P., Lawler J., Amiral J., Quentin G., and Delmas P. Identification of cell adhesive sites in the N-terminal domain of thrombospondin-1. Biochem J 321 (1997) 819-827
57. Lawler J., Ferro P., and Duquette M. Expression and mutagenesis of thrombospondin. Biochemistry 31 (1992) 1173-1180
58. Ambrosini G., Adida C., Sirugo G., and Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273 (1998) 11177-11182
59. Bellon G., Martiny L., and Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 49 (2004) 203-220
60. Scarpino S., Di Napoli A., Taraboletti G., Cancrini A., and Ruco L.P. Hepatocyte growth factor (HGF) downregulates thrombospondin-1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol 205 (2005) 50-56
61. YeeKO, Streit M., Hawighorst T., Detmer M., and Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor. Am J Pathol 165 (2004) 541-552
62. Rendtlew D.J.M., Knudsen L.M., Dahl I.M., Lodahl M., and Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 138 (2007) 756-760
63. Fukayama M., Ibuka T., Hayashi Y., Oaba T., Koike M., and Mizutani S. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol 143 (1993) 1044-1049
64. Timms J.M., Flavell J.R., Murray P.G., Rickinson A.B., Traverse- Glehen A., Berger F., et al. Target cells of Epstein-Barr-virus (EBV)-positive posttransplant lymphoproliferative disease: similarities to EBV-positive-Hodgkin's lymphoma. Lancet 361 (2003) 217-223
65. Horenstein M.G., Nador R.G., Chadburn A., Hyjek E.M., Inghirami G., Knowles D.M., et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpes virus/human herpesvirus-8. Blood 90 (1997) 1186-1191
66. Siu L.L., Chan J.K., and Kwang Y.L. Natural killer cell malignancies: clinicopathological and molecular features. Histol Histopathol 17 (2002) 539-554
67. Raphael M., Borisch B., and Jaffe E.S. Lymphomas associated with infection by the human immunodeficiency virus (HIV). In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon
68. Lee O.J., Kim K.W., and Lee G.K. Epstein-Barr virus and human immunodeficiency virus-negative oral plasmablastic lymphoma. J Oral Pathol Med 35 (2006) 382-384
69. Trivedi P., Takazawa K., Zompetta C., et al. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood 103 (2004) 313-316
70. Hamilton-Dutoit S.J., Rea D., Raphael M., et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 143 (1993) 1072-1085
71. d'Amore F., Johansen P., Houmand A., Weisenburger D.D., and Mortensen L.S. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 87 (1996) 1045-1055
72. Glaser S.L., Gulley M.L., Borowitz M.J., Craig F.E., Mann R.B., Stewart S.L., et al. Inter and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma 45 (2004) 489-547
73. Kwon J.M., Park Y.H., Kang J.H., Kim K., Ko Y.H., Ryoo B.Y., et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 85 (2006) 463-468
74. Park S., Lee, Ko Y.H., Han A., Jun H.J., Lee S.C., et al. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood 110 (2007) 972-978
75. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., and Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 91 (2000) 1233-1240
76. Shimoyama Y., Yamamoto K., Asano N., Oyama T., Kinoshita T., and Nakamura S. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci (2008) 1-7
77. Turini M.E., and DuBois R.N. Cyclooxygenase-2A therapeutic target. Annu Rev Med 53 (2002) 35-57
78. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
79. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expressionin human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 94 (1997) 3336-3340
80. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
81. Pathak S.K., Sharma R.A., Steward W.P., Mellon J.K., Griffiths T.R.L., and Gescher A.J. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer 41 (2005) 61-70
82. Tucker O.N., Dannanberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
83. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkonen M. Cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57 (1997) 1276-1280
84. TsimberidouAM, Keating M.J., Bueso-Ramos C.E., and Kurzrock R. Epstein- Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47 (2006) 827-836
85. Ladetto M., Vallet S., Trojan A., Dell'Aquilla M., Monitillo L., Rosato R., et al. Cyclooxygenase-2 is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105 (2005) 4784-4791
86. Hazar B., Ergin M., Seyrek E., Erdogan S., Tuncer I., and Hakverdi S. Cyclooxygenase-2 expression in lymphomas. Leuk Lymphoma 45 (2004) 1395-1399
87. Yoshizaki T., Horikawa T., Quing-Chun R., Wakisaka H., Takeshita H., Sheen T.S., et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 7 (2001) 1946-1951
88. Wakisaka N., Kondo S., Yoshizaki T., Murono S., Furukawa M., and Pagano J.S. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia inducible factor 1 alpha. Mol Cell Biol 24 (2004) 5223-5234
89. Mainou-Fowler T., Overman L.M., Dignum H., Wood K., Crosier S., Angus B., et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32 1 (2008 Jan) 59-68
90. Kuttler F., Valnet-Rabier M.B., Angonin R., Ferrand C., Deconinck E., Mougin C., et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16 4 (2002 Apr) 726-735
91. Dudek A.Z., Bodempudi V., Welsh B.W., Jasinski P., Griffin R.J., Milbauer L., et al. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer 97 (2007) 513-522
92. Buckstein R., Kerbel R.S., Shaked Y., Nayar R., Foden C., Turner R., et al. High-dose celecoxib and metronomic Low-dose cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12 (2006) 5190-5198
93. Ganjoo K.N., An C.S., Robertson M.J., Gordon L.I., Sen J.A., Weisenbach J., et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 47 (2006) 998-1005